Tirofiban: A Review of its Use in Patients with ST and Non ST Elevation Myocardial Infarction
Clinical Medicine Reviews in Vascular Health · 2010
DOI: 10.4137/cmrvh.s1548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine Reviews in Vascular Health, 2010.
Abstract (Originalsprache)
Acute coronary syndrome is one of the major health problems worldwide and accounts for a great number of cardiac hospitalizations in the Western world. Atherosclerotic plaque rupture or erosion followed by platelet activation and total occlusion of a coronary artery is involved in the pathogenesis of acute coronary syndrome and myocardial infarction. The glycoprotein IIb/IIIa receptor, a platelet surface integrin, plays a key role in platelet aggregation once it has been activated. In order to improve myocardial tissue reperfusion, platelet inhibition with glycoprotein IIb/IIIa inhibitors (in combination with aspirin, clopidogrel, and heparin) has been shown as beneficial adjuvant therapy in patients with acute myocardial infarction. Tirofiban is a glycoprotein IIb/IIIa inhibitor. This article reviews the data concerning its use in patients with ST elevation myocardial infarction, the pharmacokinetic profile, contraindications, an adjuvant anticoagulation therapy and the surveillance.
Zitieren
APA
(2010). Tirofiban: A Review of its Use in Patients with ST and Non ST Elevation Myocardial Infarction. Clinical Medicine Reviews in Vascular Health. https://doi.org/10.4137/cmrvh.s1548
Vancouver
Tirofiban: A Review of its Use in Patients with ST and Non ST Elevation Myocardial Infarction. Clinical Medicine Reviews in Vascular Health. 2010. doi:10.4137/cmrvh.s1548
BibTeX
@article{euvimed2010,
title = {Tirofiban: A Review of its Use in Patients with ST and Non ST Elevation Myocardial Infarction},
journal = {Clinical Medicine Reviews in Vascular Health},
year = {2010},
doi = {10.4137/cmrvh.s1548}
}
EUVIMED